Home › Trials › NCT05399524

Improving surgery for glioblastoma using advanced imaging techniques

FUTURE-GB Trial (Functional and Ultrasound-guided Resection of Glioblastoma) A 2-Stage Trial. A Learning Phase Evaluation of Participating Centres, Followed by a Randomised, Controlled Multicentre Phase III Trial.

NA · University of Oxford · NCT05399524

This study is testing if using advanced imaging techniques during surgery can help people with glioblastoma have better outcomes compared to standard surgery.

Quick facts

PhaseNA
Study typeInterventional
Enrollment357 (estimated)
Ages18 Years to 70 Years
SexAll
SponsorUniversity of Oxford (other)
Drugs / interventionschemotherapy
Locations24 sites (Birmingham and 23 other locations)
Trial IDNCT05399524 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the effectiveness of functional and ultrasound-guided resection techniques for glioblastoma. In the first stage, all participants will receive advanced imaging technologies during surgery, while the second stage will involve a randomized comparison between standard care and enhanced imaging techniques. Participants will undergo preoperative MRI scans, and those in the experimental group will receive additional diffusion tensor imaging (DTI) scans. The study will follow participants for 24 months post-surgery to assess outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-70 with a primary glioblastoma tumor deemed maximally resectable by a neuro-oncology team.

Not a fit: Patients with midline, basal ganglia, cerebellum, brainstem glioblastomas, or those with recurrent or multifocal tumors may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to improved surgical outcomes and survival rates for patients with glioblastoma.

How similar studies have performed: Other studies have shown promising results with advanced imaging techniques in neurosurgery, suggesting potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age 18-70 years
* Neuro-oncology Multi-Disciplinary Team (MDT) decision that the imaging shows a primary GB tumour which is maximally resectable (attempted gross total resection of all enhancing tumour)
* Patient is suitable for concomitant adjuvant radiotherapy and Temozolomide (TMZ) chemotherapy or adjuvant TMZ at the time of MDT decision
* Able to receive 5-ALA
* Willing and able to give informed consent
* Able to complete trial questionnaires, this may be with support where English is not their first language. (Stage 2 only)
* Able to provide a proxy who is willing to complete questionnaires as requested (Stage 2 only).

Exclusion Criteria:

* Midline/basal ganglia/cerebellum/brainstem GB
* Multifocal GB
* Recurrent GB
* Suspected secondary GB
* Contraindication to MRI

Where this trial is running

Birmingham and 23 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Glioma Glioblastoma Multiforme, DTI, iUS

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.